No. Patients | Stage | Treatments | Doses (mg/d) | SLEDAI score | Clinical Features |
---|---|---|---|---|---|
1 | inactive | - | - | 4 | PI |
2 | inactive | PRD, AZT | 5, 50 | 0 | - |
3 | inactive | PRD, AZT | 35, 12.5 | 4 | RA, MU |
4 | inactive | PRD, AZT | 5, 25 | 1 | FE |
5 | inactive | PRD | N/A | 5 | RA, MU, FE |
6 | inactive | PRD | 2.5 | 0 | - |
7 | inactive | PRD, CPM | 10, N/A | 4 | PU |
8 | inactive | PRD | 5 | 4 | AR |
9 | inactive | - | - | 4 | PU |
10 | inactive | PRD | 5 | 0 | - |
11 | inactive | PRD, AZT | 10, 50 | 4 | PU |
12 | inactive | PRD, CPM | 7.5, 25 | 0 | - |
13 | inactive | PRD, CPM | 10, 25 | 4 | PU |
14 | inactive | PRD | 10 | 2 | MU |
15 | inactive | PRD, AZT | 7.5, 100 | 5 | PU, LP |
16 | inactive | - | - | 0 | - |
17 | active | PRD, AZT | 5, 100 | 8 | HE, PU |
18 | active | - | - | 8 | HE, PU |
19 | active | PRD, MMF | 2.5, 2,000 | 8 | HE, PU |
20 | active | PRD | 15 | 30 | SZ, UC, HE, PU, PI, PE, LC, IDB |
21 | active | PRD, AZT | 5, 25 | 11 | MY, HE, PL, LP |
22 | active | PRD | 5 | 8 | AR, PU |
23 | active | PRD, AZT | 30, 50 | 29 | VA, AR, HE, PU, PI, RA, MU, LP |
24 | active | PRD | 30 | 11 | PU, AL, PL, FE, TC, LP |
25 | active | PRD, AZT | 5, 50 | 8 | VA |
26 | active | PRD, MMF | 5, 500 | 13 | HE, PU, AL, MU, LP |
27 | active | PRD | 20 | 12 | HE, PU, PI |
28 | active | PRD, AZT | 20, 25 | 16 | VA, PU, MU, LC |
29 | active | PRD | 15 | 6 | PU, LC |